Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study is investigating the combination of palbociclib, letrozole and venetoclax in ER
and BCL-2 positive locally advanced or metastatic breast cancer.
It is hypothesised that venetoclax may augment the actions of palbociclib and letrozole in
these patient groups. The primary objective of the study is to determine the maximum
tolerated dose of the combination treatment, which can be used in subsequent studies. The
study will also investigate disease response and survival.
Participants will receive palbociclib (daily, on days 1-21 of each 28 day cycle), letrozole
(daily, on days 1-28 of each 28 day cycle) and venetoclax (daily, on days 1-21 of each 28 day
cycle) until the last patient has completed 18 months treatment on the study.